Phase 3 study for people with Melanoma

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Immunocore Ltd
Registry number NCT06112314
Started 5 June 2024 Today 16 October 2026 Estimated completion 16 October 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Calvary Mater Newcastle Hospital Waratah NSW Recruiting
Gallipoli Medical Research Foundation (Greenslopes Private Hospital) Greenslopes QLD Completed
Linear Clinical Research Nedlands WA Recruiting
One Clinical Research - Nedlands Nedlands WA Recruiting
Austin Hospital Heidelberg VIC Recruiting
Peter MacCallum Cancer Centre North Melbourne VIC Recruiting
University of Sydney - Melanoma Institute Australia (MIA) - The Poche Centre Wollstonecraft Australia Recruiting
The University of Queensland (UQ) - Princess Alexandra Hospital (PAH) Woolloongabba Australia Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 680

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Participants must be HLA-A\*02:01-positive

* Participants must have histologically confirmed Stage IV or unresectable Stage III melanoma

* Archived or fresh tumor tissue sample that must be confirmed as adequate

* Participants must have measurable disease per RECIST 1.1

* Participant must have BRAF V600 mutation status determined

* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the study screening date until 5 months after the final dose of study intervention

Exclusion Criteria:

* Participants with a history of a malignant disease other than those being treated in this study

* Participants with untreated, active, or symptomatic central nervous system (CNS) metastases or carcinomatous meningitis

* Hypersensitivity to IMC-F106C, nivolumab, relatlimab, or any associated excipients

* Participants with clinically significant pulmonary disease or impaired lung function

* Participants with clinically significant cardiac disease or impaired cardiac function

* Participants with active autoimmune disease requiring immunosuppressive treatment

* Participants with any medical condition that is poorly controlled or that would, in the Investigator's or Sponsor's judgment, adversely impact the participant's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results

* Participants who received prior systemic anticancer therapy for unresectable or metastatic melanoma

* Participants with a history of a life-threatening AE related to prior anti-PD-(L)1 or anti-LAG-3

Dates on the record

Started 5 June 2024
Estimated completion 16 October 2027
Registry last updated 25 February 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 25 February 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.